LataMed AI Corp. (OTC: LMED), a development-stage digital health and artificial intelligence technology company, announced today that management has begun planning for the Company's anticipated attendance at the World Health Expo 2027 in Dubai, United Arab Emirates. This initiative is part of a broader strategy to evaluate international healthcare expansion opportunities beyond its current Latin American initiatives.
Management believes attendance at World Health Expo 2027 will provide an important opportunity to engage with healthcare leaders, technology innovators, healthcare providers, government representatives, and potential strategic partners from around the world. The Company sees this as a chance to evaluate potential strategic relationships, licensing opportunities, and regional collaborations relating to its digital healthcare technologies, while gaining insight into emerging trends in healthcare innovation, precision medicine, artificial intelligence, and digital health infrastructure.
The planned participation builds upon recent international engagement initiatives, including attendance at HLTH Europe, and complements LataMed's continued expansion throughout Latin America. This includes recently announced strategic initiatives in Venezuela and ongoing evaluation of expansion opportunities in Colombia.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., stated: "As we continue executing our long-term vision of building an integrated digital healthcare ecosystem, we believe it is important to evaluate opportunities beyond our existing markets. World Health Expo 2027 is expected to provide an outstanding opportunity to engage with healthcare leaders from around the world, better understand evolving global healthcare trends, and explore potential strategic relationships that may support the continued development and international expansion of the LataMed AI platform."
Management emphasized that attendance remains in the planning stage and forms part of a broader evaluation of future international growth opportunities. No assurance can be provided regarding the completion of any strategic relationships, licensing arrangements, commercial agreements, international expansion initiatives, or other opportunities that may arise from the Company's planned attendance.
In a separate announcement, the Company confirmed that FINRA has approved its previously announced 5-for-1 forward stock split and mandatory share exchange, expected to become effective at the opening of trading on Wednesday, July 15, 2026, subject to completion of customary administrative processing. Shareholders holding shares through brokerage accounts or in electronic book-entry form generally are not expected to take any action, while those holding physical stock certificates may exchange them through the Company's transfer agent in accordance with mandatory exchange procedures.
The Company looks forward to completing this important corporate milestone as it continues focusing on the expansion of its telemedicine platform and the commercialization of its CardioAI, PulmoAI, and NeuroAI artificial intelligence platforms.
LataMed AI's strategy is centered on developing technology platforms designed to support healthcare access, patient engagement, provider coordination, emergency medical response, pharmacy integration, insurance accessibility, payment solutions, and data-driven healthcare operations, with an initial regional focus on Latin America. The Company's planned participation at World Health Expo 2027 represents a potential step toward global reach, though management cautions that it remains in the planning stages and subject to risks and uncertainties.
For additional information, please visit https://latamed.ai or review the Company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
